Evogene Stock News

Evogene (EVGN) delivered earnings and revenue surprises of -16.67% and 83.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Dr. Elran Haber to participate in the Industry Leaders opening panel  at this premier Microbiome conference REHOVOT, Israel , June 15, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutica

Evogene Ltd. (NASDAQ:EVGN ) Q1 2022 Results Conference Call May 26, 2022 9:00 AM ET Company Participants Ofer Haviv - CEO, President & Chairman Elran Haber - CEO, Biomica Yaron Eldad - CFO Conference

Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus.

During the last session, Evogene Ltd. (NASDAQ:EVGN)’s traded shares were 2.9 million, with the beta value of the company hitting 1.30. At the end of the trading day, the stock’s price was $1.39, reflecting an intraday gain of 7.75% or $0.1. The 52-week high for the EVGN share is $5.99, that puts it down -330.94 … How Evogene Ltd. (NASDAQ: EVGN) Could Be A Loss Maker Since It Is Down -15.24% YTD? Read More »

Evogene Ltd (EVGN) CEO Ofer Haviv on Q4 2021 Results - Earnings Call Transcript

Evogene press release (EVGN): Q4 GAAP EPS of -$0.18 beats by $0.02.Revenue of $0.31M (-11.4% Y/Y) beats by $0.14M.

Evogene (EVGN) delivered earnings and revenue surprises of 10% and 107.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.

Evogene (NASDAQ:EVGN) is scheduled to announce Q4 results on Thursday, Mar. 10, before market open.Consensus EPS estimate is -$0.20 and consensus revenue estimate is $0.17M (-51.4% Y/Y).

Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries.

In the latest trading session, 0.95 million Evogene Ltd. (NASDAQ:EVGN) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $1.20 changing hands around $0.08 or 7.15% at last look, the market valuation stands at $46.10M. EVGN’s current price is a discount, trading about -431.67% off its … Evogene Ltd. (NASDAQ: EVGN) Is Becoming An Interest-Losing Stock With A 7.15% Incline Read More »